KMT2A is altered in 2.49% of acute myeloid leukemia patients [3].

KMT2A is an inclusion criterion in 158 clinical trials for acute myeloid leukemia, of which 86 are open and 72 are closed. Of the trials that contain KMT2A status and acute myeloid leukemia as inclusion criteria, 2 are early phase 1 (1 open), 46 are phase 1 (20 open), 27 are phase 1/phase 2 (19 open), 61 are phase 2 (35 open), 5 are phase 2/phase 3 (4 open), 13 are phase 3 (7 open), and 4 are no phase specified (0 open) [4].

KMT2A is altered in 1.11% of myelodysplastic syndromes patients [3].

KMT2A is an inclusion criterion in 76 clinical trials for myelodysplastic syndromes, of which 47 are open and 29 are closed. Of the trials that contain KMT2A status and myelodysplastic syndromes as inclusion criteria, 2 are early phase 1 (1 open), 26 are phase 1 (14 open), 11 are phase 1/phase 2 (10 open), 31 are phase 2 (19 open), 2 are phase 2/phase 3 (1 open), 3 are phase 3 (2 open), and 1 is no phase specified (0 open) [4].

KMT2A is an inclusion criterion in 66 clinical trials for acute lymphoblastic leukemia, of which 42 are open and 24 are closed. Of the trials that contain KMT2A status and acute lymphoblastic leukemia as inclusion criteria, 2 are early phase 1 (1 open), 22 are phase 1 (12 open), 9 are phase 1/phase 2 (8 open), 25 are phase 2 (15 open), 1 is phase 2/phase 3 (1 open), 4 are phase 3 (3 open), 1 is phase 4 (1 open), and 2 are no phase specified (1 open) [4].

KMT2A is altered in 4.35% of chronic myeloid leukemia patients [3].

KMT2A is an inclusion criterion in 33 clinical trials for chronic myeloid leukemia, of which 22 are open and 11 are closed. Of the trials that contain KMT2A status and chronic myeloid leukemia as inclusion criteria, 1 is early phase 1 (0 open), 12 are phase 1 (8 open), 6 are phase 1/phase 2 (6 open), 13 are phase 2 (8 open), and 1 is no phase specified (0 open) [4].

KMT2A is an inclusion criterion in 24 clinical trials for primary myelofibrosis, of which 22 are open and 2 are closed. Of the trials that contain KMT2A status and primary myelofibrosis as inclusion criteria, 4 are phase 1 (4 open), 2 are phase 1/phase 2 (2 open), 9 are phase 2 (7 open), 1 is phase 2/phase 3 (1 open), and 8 are phase 3 (8 open) [4].

KMT2A is an inclusion criterion in 22 clinical trials for hodgkin lymphoma, of which 13 are open and 9 are closed. Of the trials that contain KMT2A status and hodgkin lymphoma as inclusion criteria, 1 is early phase 1 (0 open), 9 are phase 1 (4 open), 2 are phase 1/phase 2 (2 open), 9 are phase 2 (7 open), and 1 is no phase specified (0 open) [4].

KMT2A is an inclusion criterion in 21 clinical trials for myelofibrosis, of which 16 are open and 5 are closed. Of the trials that contain KMT2A status and myelofibrosis as inclusion criteria, 2 are early phase 1 (0 open), 8 are phase 1 (6 open), 3 are phase 1/phase 2 (3 open), 5 are phase 2 (4 open), and 3 are phase 3 (3 open) [4].

KMT2A is altered in 3.58% of non-hodgkin lymphoma patients [3].

KMT2A is an inclusion criterion in 19 clinical trials for non-hodgkin lymphoma, of which 12 are open and 7 are closed. Of the trials that contain KMT2A status and non-hodgkin lymphoma as inclusion criteria, 2 are early phase 1 (1 open), 7 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), and 9 are phase 2 (7 open) [4].

KMT2A is altered in 2.07% of chronic myelomonocytic leukemia patients [3].

KMT2A is an inclusion criterion in 18 clinical trials for chronic myelomonocytic leukemia, of which 13 are open and 5 are closed. Of the trials that contain KMT2A status and chronic myelomonocytic leukemia as inclusion criteria, 8 are phase 1 (5 open), 3 are phase 1/phase 2 (3 open), 6 are phase 2 (5 open), and 1 is phase 3 (0 open) [4].

KMT2A is altered in 2.52% of multiple myeloma patients [3].

KMT2A is an inclusion criterion in 17 clinical trials for multiple myeloma, of which 12 are open and 5 are closed. Of the trials that contain KMT2A status and multiple myeloma as inclusion criteria, 1 is early phase 1 (1 open), 7 are phase 1 (5 open), 2 are phase 1/phase 2 (2 open), 6 are phase 2 (4 open), and 1 is no phase specified (0 open) [4].

KMT2A is an inclusion criterion in 16 clinical trials for acute biphenotypic leukemia, of which 7 are open and 9 are closed. Of the trials that contain KMT2A status and acute biphenotypic leukemia as inclusion criteria, 6 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), 6 are phase 2 (3 open), 2 are phase 3 (0 open), and 1 is no phase specified (0 open) [4].

KMT2A is an inclusion criterion in 16 clinical trials for myelofibrosis transformation in essential thrombocythemia, of which 15 are open and 1 is closed. Of the trials that contain KMT2A status and myelofibrosis transformation in essential thrombocythemia as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), 4 are phase 2 (3 open), and 8 are phase 3 (8 open) [4].

KMT2A is an inclusion criterion in 16 clinical trials for polycythemia vera, post-polycythemic myelofibrosis phase, of which 15 are open and 1 is closed. Of the trials that contain KMT2A status and polycythemia vera, post-polycythemic myelofibrosis phase as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), 4 are phase 2 (3 open), and 8 are phase 3 (8 open) [4].

KMT2A is an inclusion criterion in 15 clinical trials for chronic lymphocytic leukemia, of which 10 are open and 5 are closed. Of the trials that contain KMT2A status and chronic lymphocytic leukemia as inclusion criteria, 1 is early phase 1 (0 open), 5 are phase 1 (2 open), 3 are phase 1/phase 2 (3 open), 5 are phase 2 (5 open), and 1 is phase 3 (0 open) [4].

KMT2A is altered in 2.47% of acute leukemia patients [3].

KMT2A is an inclusion criterion in 12 clinical trials for acute leukemia, of which 6 are open and 6 are closed. Of the trials that contain KMT2A status and acute leukemia as inclusion criteria, 3 are phase 1 (0 open), 4 are phase 1/phase 2 (4 open), 3 are phase 2 (2 open), 1 is phase 3 (0 open), and 1 is no phase specified (0 open) [4].

KMT2A is altered in 0.91% of myeloproliferative neoplasm patients [3].

KMT2A is an inclusion criterion in 11 clinical trials for myeloproliferative neoplasm, of which 5 are open and 6 are closed. Of the trials that contain KMT2A status and myeloproliferative neoplasm as inclusion criteria, 3 are phase 1 (1 open), 1 is phase 1/phase 2 (1 open), 6 are phase 2 (3 open), and 1 is no phase specified (0 open) [4].

KMT2A is an inclusion criterion in 11 clinical trials for Burkitt lymphoma, of which 5 are open and 6 are closed. Of the trials that contain KMT2A status and Burkitt lymphoma as inclusion criteria, 4 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), 4 are phase 2 (2 open), 1 is phase 3 (0 open), and 1 is no phase specified (0 open) [4].

KMT2A is altered in 1.69% of mantle cell lymphoma patients [3].

KMT2A is an inclusion criterion in 10 clinical trials for mantle cell lymphoma, of which 5 are open and 5 are closed. Of the trials that contain KMT2A status and mantle cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open), 4 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), 3 are phase 2 (1 open), and 1 is no phase specified (0 open) [4].

KMT2A is altered in 1.56% of secondary acute myeloid leukemia patients [3].

KMT2A is an inclusion criterion in 9 clinical trials for secondary acute myeloid leukemia, of which 9 are open and 0 are closed. Of the trials that contain KMT2A status and secondary acute myeloid leukemia as inclusion criteria, 3 are phase 1 (3 open), 2 are phase 1/phase 2 (2 open), and 4 are phase 2 (4 open) [4].

KMT2A is an inclusion criterion in 9 clinical trials for B-cell acute lymphoblastic leukemia, of which 9 are open and 0 are closed. Of the trials that contain KMT2A status and B-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), 5 are phase 2 (5 open), and 2 are phase 3 (2 open) [4].

KMT2A is an inclusion criterion in 9 clinical trials for secondary myelofibrosis, of which 8 are open and 1 is closed. Of the trials that contain KMT2A status and secondary myelofibrosis as inclusion criteria, 2 are phase 1 (2 open), 6 are phase 2 (5 open), and 1 is phase 2/phase 3 (1 open) [4].

KMT2A is altered in 2.7% of anaplastic large cell lymphoma patients [3].

KMT2A is an inclusion criterion in 8 clinical trials for anaplastic large cell lymphoma, of which 4 are open and 4 are closed. Of the trials that contain KMT2A status and anaplastic large cell lymphoma as inclusion criteria, 3 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), 3 are phase 2 (1 open), and 1 is no phase specified (0 open) [4].

KMT2A is altered in 3.66% of marginal zone lymphoma patients [3].

KMT2A is an inclusion criterion in 7 clinical trials for marginal zone lymphoma, of which 3 are open and 4 are closed. Of the trials that contain KMT2A status and marginal zone lymphoma as inclusion criteria, 3 are phase 1 (2 open), 3 are phase 2 (1 open), and 1 is no phase specified (0 open) [4].

KMT2A is altered in 2.78% of follicular lymphoma patients [3].

KMT2A is an inclusion criterion in 7 clinical trials for follicular lymphoma, of which 3 are open and 4 are closed. Of the trials that contain KMT2A status and follicular lymphoma as inclusion criteria, 3 are phase 1 (2 open), 3 are phase 2 (1 open), and 1 is no phase specified (0 open) [4].

KMT2A is altered in 1.44% of myelodysplastic/myeloproliferative neoplasm patients [3].

KMT2A is an inclusion criterion in 7 clinical trials for myelodysplastic/myeloproliferative neoplasm, of which 6 are open and 1 is closed. Of the trials that contain KMT2A status and myelodysplastic/myeloproliferative neoplasm as inclusion criteria, 2 are phase 1 (2 open), 2 are phase 1/phase 2 (2 open), and 3 are phase 2 (2 open) [4].

KMT2A is an inclusion criterion in 7 clinical trials for juvenile myelomonocytic leukemia, of which 3 are open and 4 are closed. Of the trials that contain KMT2A status and juvenile myelomonocytic leukemia as inclusion criteria, 2 are phase 1 (0 open), 1 is phase 1/phase 2 (1 open), 3 are phase 2 (1 open), and 1 is phase 3 (1 open) [4].

KMT2A is altered in 1.56% of therapy-related acute myeloid leukemia patients [3].

KMT2A is an inclusion criterion in 6 clinical trials for therapy-related acute myeloid leukemia, of which 6 are open and 0 are closed. Of the trials that contain KMT2A status and therapy-related acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) and 5 are phase 2 (5 open) [4].

KMT2A is altered in 5.1% of diffuse large B-cell lymphoma patients [3].

KMT2A is an inclusion criterion in 6 clinical trials for diffuse large B-cell lymphoma, of which 5 are open and 1 is closed. Of the trials that contain KMT2A status and diffuse large B-cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open), 3 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [4].

KMT2A is altered in 3.57% of lymphoma patients [3].

KMT2A is an inclusion criterion in 6 clinical trials for lymphoma, of which 3 are open and 3 are closed. Of the trials that contain KMT2A status and lymphoma as inclusion criteria, 2 are phase 1 (0 open), 2 are phase 2 (2 open), and 2 are phase 3 (1 open) [4].

KMT2A is an inclusion criterion in 6 clinical trials for acute myeloid leukemia arising from previous myelodysplastic syndrome, of which 6 are open and 0 are closed. Of the trials that contain KMT2A status and acute myeloid leukemia arising from previous myelodysplastic syndrome as inclusion criteria, 1 is phase 1 (1 open) and 5 are phase 2 (5 open) [4].

KMT2A is an inclusion criterion in 6 clinical trials for mixed phenotype acute leukemia, of which 5 are open and 1 is closed. Of the trials that contain KMT2A status and mixed phenotype acute leukemia as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 4 are phase 2 (3 open) [4].

KMT2A is an inclusion criterion in 6 clinical trials for prolymphocytic leukemia, of which 3 are open and 3 are closed. Of the trials that contain KMT2A status and prolymphocytic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open), 3 are phase 2 (2 open), 1 is phase 3 (0 open), and 1 is no phase specified (0 open) [4].

KMT2A is an inclusion criterion in 6 clinical trials for refractory anemia with excess blasts, of which 3 are open and 3 are closed. Of the trials that contain KMT2A status and refractory anemia with excess blasts as inclusion criteria, 3 are phase 1 (1 open) and 3 are phase 2 (2 open) [4].

KMT2A is altered in 1.69% of chronic lymphocytic leukemia/small lymphocytic lymphoma patients [3].

KMT2A is an inclusion criterion in 5 clinical trials for chronic lymphocytic leukemia/small lymphocytic lymphoma, of which 2 are open and 3 are closed. Of the trials that contain KMT2A status and chronic lymphocytic leukemia/small lymphocytic lymphoma as inclusion criteria, 1 is phase 1 (1 open), 3 are phase 2 (1 open), and 1 is no phase specified (0 open) [4].

KMT2A is an inclusion criterion in 5 clinical trials for acute undifferentiated leukemia, of which 4 are open and 1 is closed. Of the trials that contain KMT2A status and acute undifferentiated leukemia as inclusion criteria, 2 are phase 1 (2 open), 2 are phase 2 (2 open), and 1 is phase 3 (0 open) [4].

KMT2A is an inclusion criterion in 5 clinical trials for double-hit lymphoma, of which 3 are open and 2 are closed. Of the trials that contain KMT2A status and double-hit lymphoma as inclusion criteria, 1 is early phase 1 (1 open), 3 are phase 1 (1 open), and 1 is phase 2 (1 open) [4].

KMT2A is an inclusion criterion in 5 clinical trials for myelodysplastic syndrome with excess blasts-2, of which 3 are open and 2 are closed. Of the trials that contain KMT2A status and myelodysplastic syndrome with excess blasts-2 as inclusion criteria, 1 is phase 1 (1 open) and 4 are phase 2 (2 open) [4].

KMT2A is an inclusion criterion in 5 clinical trials for small lymphocytic lymphoma, of which 2 are open and 3 are closed. Of the trials that contain KMT2A status and small lymphocytic lymphoma as inclusion criteria, 4 are phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [4].

KMT2A is an inclusion criterion in 5 clinical trials for T-cell acute lymphoblastic leukemia, of which 5 are open and 0 are closed. Of the trials that contain KMT2A status and T-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), 2 are phase 2 (2 open), and 1 is phase 3 (1 open) [4].

KMT2A is altered in 2.0% of therapy-related myelodysplastic syndrome patients [3].

KMT2A is an inclusion criterion in 4 clinical trials for therapy-related myelodysplastic syndrome, of which 4 are open and 0 are closed. Of the trials that contain KMT2A status and therapy-related myelodysplastic syndrome as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [4].

KMT2A is an inclusion criterion in 4 clinical trials for lymphoblastic lymphoma, of which 3 are open and 1 is closed. Of the trials that contain KMT2A status and lymphoblastic lymphoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 2 are phase 2 (1 open) [4].

KMT2A is an inclusion criterion in 4 clinical trials for lymphoplasmacytic lymphoma, of which 1 is open and 3 are closed. Of the trials that contain KMT2A status and lymphoplasmacytic lymphoma as inclusion criteria, 3 are phase 2 (1 open) and 1 is no phase specified (0 open) [4].

KMT2A is altered in 5.63% of T-cell lymphoblastic leukemia/lymphoma patients [3].

KMT2A is an inclusion criterion in 3 clinical trials for T-cell lymphoblastic leukemia/lymphoma, of which 2 are open and 1 is closed. Of the trials that contain KMT2A status and T-cell lymphoblastic leukemia/lymphoma as inclusion criteria, 3 are phase 1 (2 open) [4].

KMT2A is altered in 3.61% of B-cell non-hodgkin lymphoma patients [3].

KMT2A is an inclusion criterion in 3 clinical trials for B-cell non-hodgkin lymphoma, of which 2 are open and 1 is closed. Of the trials that contain KMT2A status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [4].

KMT2A is an inclusion criterion in 3 clinical trials for plasma cell leukemia, of which 1 is open and 2 are closed. Of the trials that contain KMT2A status and plasma cell leukemia as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 2 (1 open) [4].

KMT2A is an inclusion criterion in 3 clinical trials for refractory anemia, of which 1 is open and 2 are closed. Of the trials that contain KMT2A status and refractory anemia as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 2 (1 open) [4].

KMT2A is altered in 1.18% of acute myeloid leukemia with myelodysplasia-related changes patients [3].

KMT2A is an inclusion criterion in 2 clinical trials for acute myeloid leukemia with myelodysplasia-related changes, of which 1 is open and 1 is closed. Of the trials that contain KMT2A status and acute myeloid leukemia with myelodysplasia-related changes as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 2/phase 3 (0 open) [4].

KMT2A is altered in 3.28% of mature T-cell and NK-cell neoplasm patients [3].

KMT2A is an inclusion criterion in 2 clinical trials for mature T-cell and NK-cell neoplasm, of which 1 is open and 1 is closed. Of the trials that contain KMT2A status and mature T-cell and NK-cell neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (0 open) [4].

KMT2A is altered in 2.04% of acute leukemia of ambiguous lineage patients [3].

KMT2A is an inclusion criterion in 2 clinical trials for acute leukemia of ambiguous lineage, of which 1 is open and 1 is closed. Of the trials that contain KMT2A status and acute leukemia of ambiguous lineage as inclusion criteria, 2 are phase 2 (1 open) [4].

KMT2A is an inclusion criterion in 2 clinical trials for acute erythroid leukemia, of which 2 are open and 0 are closed. Of the trials that contain KMT2A status and acute erythroid leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [4].

KMT2A is an inclusion criterion in 2 clinical trials for acute megakaryoblastic leukemia, of which 2 are open and 0 are closed. Of the trials that contain KMT2A status and acute megakaryoblastic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [4].

KMT2A is an inclusion criterion in 2 clinical trials for acute promyelocytic leukemia, of which 0 are open and 2 are closed. Of the trials that contain KMT2A status and acute promyelocytic leukemia as inclusion criteria, 1 is phase 1 (0 open) and 1 is no phase specified (0 open) [4].

KMT2A is an inclusion criterion in 2 clinical trials for adult T-cell leukemia/lymphoma, of which 0 are open and 2 are closed. Of the trials that contain KMT2A status and adult T-cell leukemia/lymphoma as inclusion criteria, 1 is phase 3 (0 open) and 1 is no phase specified (0 open) [4].

KMT2A is an inclusion criterion in 2 clinical trials for atypical chronic myeloid leukemia, BCR-ABL1 negative, of which 1 is open and 1 is closed. Of the trials that contain KMT2A status and atypical chronic myeloid leukemia, BCR-ABL1 negative as inclusion criteria, 1 is phase 1 (1 open) and 1 is no phase specified (0 open) [4].

KMT2A is an inclusion criterion in 2 clinical trials for B-cell prolymphocytic leukemia, of which 1 is open and 1 is closed. Of the trials that contain KMT2A status and B-cell prolymphocytic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (0 open) [4].

KMT2A is an inclusion criterion in 2 clinical trials for Burkitt leukemia, of which 2 are open and 0 are closed. Of the trials that contain KMT2A status and Burkitt leukemia as inclusion criteria, 2 are phase 1 (2 open) [4].

KMT2A is an inclusion criterion in 2 clinical trials for mature T-cell and NK-cell lymphoma/leukemia, of which 0 are open and 2 are closed. Of the trials that contain KMT2A status and mature T-cell and NK-cell lymphoma/leukemia as inclusion criteria, 1 is phase 2 (0 open) and 1 is no phase specified (0 open) [4].

KMT2A is an inclusion criterion in 2 clinical trials for mediastinal large B-cell lymphoma, of which 1 is open and 1 is closed. Of the trials that contain KMT2A status and mediastinal large B-cell lymphoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [4].

KMT2A is an inclusion criterion in 2 clinical trials for myelodysplastic syndrome with excess blasts-1, of which 2 are open and 0 are closed. Of the trials that contain KMT2A status and myelodysplastic syndrome with excess blasts-1 as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].

KMT2A is an inclusion criterion in 2 clinical trials for natural killer cell lymphoblastic leukemia/lymphoma, of which 1 is open and 1 is closed. Of the trials that contain KMT2A status and natural killer cell lymphoblastic leukemia/lymphoma as inclusion criteria, 2 are phase 2 (1 open) [4].

KMT2A is an inclusion criterion in 2 clinical trials for peripheral T-cell lymphoma, of which 1 is open and 1 is closed. Of the trials that contain KMT2A status and peripheral T-cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open) and 1 is phase 1 (0 open) [4].

KMT2A is an inclusion criterion in 2 clinical trials for T-cell prolymphocytic leukemia, of which 1 is open and 1 is closed. Of the trials that contain KMT2A status and T-cell prolymphocytic leukemia as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 1/phase 2 (1 open) [4].

KMT2A is altered in 14.29% of high grade B-cell lymphoma, not otherwise specified patients [3].

KMT2A is an inclusion criterion in 1 clinical trial for high grade B-cell lymphoma, not otherwise specified, of which 1 is open and 0 are closed. Of the trial that contains KMT2A status and high grade B-cell lymphoma, not otherwise specified as inclusion criteria, 1 is phase 2 (1 open) [4].

KMT2A is altered in 4.65% of malignant solid tumor patients [3].

KMT2A is an inclusion criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains KMT2A status and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open) [4].

KMT2A is altered in 2.0% of secondary myelodysplastic syndrome patients [3].

KMT2A is an inclusion criterion in 1 clinical trial for secondary myelodysplastic syndrome, of which 1 is open and 0 are closed. Of the trial that contains KMT2A status and secondary myelodysplastic syndrome as inclusion criteria, 1 is phase 2 (1 open) [4].

KMT2A is altered in 5.42% of diffuse large B-cell lymphoma, not otherwise specified patients [3].

KMT2A is an inclusion criterion in 1 clinical trial for diffuse large B-cell lymphoma, not otherwise specified, of which 1 is open and 0 are closed. Of the trial that contains KMT2A status and diffuse large B-cell lymphoma, not otherwise specified as inclusion criteria, 1 is phase 2 (1 open) [4].

KMT2A is altered in 3.32% of indolent non-hodgkin lymphoma patients [3].

KMT2A is an inclusion criterion in 1 clinical trial for indolent non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains KMT2A status and indolent non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

KMT2A is altered in 3.61% of T-cell and NK-cell neoplasm patients [3].

KMT2A is an inclusion criterion in 1 clinical trial for T-cell and NK-cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains KMT2A status and T-cell and NK-cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

KMT2A is altered in 2.51% of plasma cell neoplasm patients [3].

KMT2A is an inclusion criterion in 1 clinical trial for plasma cell neoplasm, of which 0 are open and 1 is closed. Of the trial that contains KMT2A status and plasma cell neoplasm as inclusion criteria, 1 is phase 1 (0 open) [4].

KMT2A is altered in 3.2% of mature T-cell and NK-cell non-hodgkin lymphoma patients [3].

KMT2A is an inclusion criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 0 are open and 1 is closed. Of the trial that contains KMT2A status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (0 open) [4].

KMT2A is altered in 3.2% of T-cell non-hodgkin lymphoma patients [3].

KMT2A is an inclusion criterion in 1 clinical trial for T-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains KMT2A status and T-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

KMT2A is altered in 3.01% of neuroblastoma patients [3].

KMT2A is an inclusion criterion in 1 clinical trial for neuroblastoma, of which 0 are open and 1 is closed. Of the trial that contains KMT2A status and neuroblastoma as inclusion criteria, 1 is phase 1 (0 open) [4].

KMT2A is altered in 2.41% of hematopoietic and lymphoid malignancy patients [3].

KMT2A is an inclusion criterion in 1 clinical trial for hematopoietic and lymphoid malignancy, of which 1 is open and 0 are closed. Of the trial that contains KMT2A status and hematopoietic and lymphoid malignancy as inclusion criteria, 1 is phase 2 (1 open) [4].

KMT2A is altered in 1.54% of therapy-related myeloid neoplasm patients [3].

KMT2A is an inclusion criterion in 1 clinical trial for therapy-related myeloid neoplasm, of which 1 is open and 0 are closed. Of the trial that contains KMT2A status and therapy-related myeloid neoplasm as inclusion criteria, 1 is phase 2/phase 3 (1 open) [4].

KMT2A is altered in 2.52% of leukemia patients [3].

KMT2A is an inclusion criterion in 1 clinical trial for leukemia, of which 1 is open and 0 are closed. Of the trial that contains KMT2A status and leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

KMT2A is altered in 1.54% of histiocytic and dendritic cell neoplasm patients [3].

KMT2A is an inclusion criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains KMT2A status and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

KMT2A is altered in 1.77% of myeloid neoplasm patients [3].

KMT2A is an inclusion criterion in 1 clinical trial for myeloid neoplasm, of which 1 is open and 0 are closed. Of the trial that contains KMT2A status and myeloid neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

KMT2A is altered in 0.66% of Ewing sarcoma patients [3].

KMT2A is an inclusion criterion in 1 clinical trial for Ewing sarcoma, of which 0 are open and 1 is closed. Of the trial that contains KMT2A status and Ewing sarcoma as inclusion criteria, 1 is phase 1 (0 open) [4].

KMT2A is altered in 1.1% of rhabdomyosarcoma patients [3].

KMT2A is an inclusion criterion in 1 clinical trial for rhabdomyosarcoma, of which 0 are open and 1 is closed. Of the trial that contains KMT2A status and rhabdomyosarcoma as inclusion criteria, 1 is phase 1 (0 open) [4].

KMT2A is an inclusion criterion in 1 clinical trial for acute bilineal leukemia, of which 1 is open and 0 are closed. Of the trial that contains KMT2A status and acute bilineal leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

KMT2A is an inclusion criterion in 1 clinical trial for adult acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains KMT2A status and adult acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1 (1 open) [4].

KMT2A is an inclusion criterion in 1 clinical trial for aplastic anemia, of which 1 is open and 0 are closed. Of the trial that contains KMT2A status and aplastic anemia as inclusion criteria, 1 is phase 1 (1 open) [4].

KMT2A is an inclusion criterion in 1 clinical trial for atypical Burkitt/Burkitt-like lymphoma, of which 1 is open and 0 are closed. Of the trial that contains KMT2A status and atypical Burkitt/Burkitt-like lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

KMT2A is an inclusion criterion in 1 clinical trial for B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains KMT2A status and B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

KMT2A is an inclusion criterion in 1 clinical trial for desmoplastic small round cell tumor, of which 0 are open and 1 is closed. Of the trial that contains KMT2A status and desmoplastic small round cell tumor as inclusion criteria, 1 is phase 1 (0 open) [4].

KMT2A is an inclusion criterion in 1 clinical trial for diffuse large B-cell lymphoma activated B-cell type, of which 1 is open and 0 are closed. Of the trial that contains KMT2A status and diffuse large B-cell lymphoma activated B-cell type as inclusion criteria, 1 is phase 2 (1 open) [4].

KMT2A is an inclusion criterion in 1 clinical trial for diffuse large B-cell lymphoma associated with chronic inflammation, of which 1 is open and 0 are closed. Of the trial that contains KMT2A status and diffuse large B-cell lymphoma associated with chronic inflammation as inclusion criteria, 1 is phase 2 (1 open) [4].

KMT2A is an inclusion criterion in 1 clinical trial for EBV-positive diffuse large B-cell lymphoma, not otherwise specified, of which 1 is open and 0 are closed. Of the trial that contains KMT2A status and EBV-positive diffuse large B-cell lymphoma, not otherwise specified as inclusion criteria, 1 is phase 2 (1 open) [4].

KMT2A is an inclusion criterion in 1 clinical trial for EBV-positive mucocutaneous ulcer, of which 1 is open and 0 are closed. Of the trial that contains KMT2A status and EBV-positive mucocutaneous ulcer as inclusion criteria, 1 is phase 2 (1 open) [4].

KMT2A is an inclusion criterion in 1 clinical trial for germinal center B-cell-like diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains KMT2A status and germinal center B-cell-like diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

KMT2A is an inclusion criterion in 1 clinical trial for HHV8-positive diffuse large B-cell lymphoma, not otherwise specified, of which 1 is open and 0 are closed. Of the trial that contains KMT2A status and HHV8-positive diffuse large B-cell lymphoma, not otherwise specified as inclusion criteria, 1 is phase 2 (1 open) [4].

KMT2A is an inclusion criterion in 1 clinical trial for intravascular large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains KMT2A status and intravascular large B-cell lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

KMT2A is an inclusion criterion in 1 clinical trial for lymphomatoid granulomatosis, of which 1 is open and 0 are closed. Of the trial that contains KMT2A status and lymphomatoid granulomatosis as inclusion criteria, 1 is phase 2 (1 open) [4].

KMT2A is an inclusion criterion in 1 clinical trial for mature B-cell lymphoma/leukemia, of which 0 are open and 1 is closed. Of the trial that contains KMT2A status and mature B-cell lymphoma/leukemia as inclusion criteria, 1 is phase 1 (0 open) [4].

KMT2A is an inclusion criterion in 1 clinical trial for myelodysplastic/myeloproliferative neoplasm, unclassifiable, of which 1 is open and 0 are closed. Of the trial that contains KMT2A status and myelodysplastic/myeloproliferative neoplasm, unclassifiable as inclusion criteria, 1 is phase 1 (1 open) [4].

KMT2A is an inclusion criterion in 1 clinical trial for myeloid sarcoma, of which 1 is open and 0 are closed. Of the trial that contains KMT2A status and myeloid sarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].

KMT2A is an inclusion criterion in 1 clinical trial for overt primary myelofibrosis, of which 1 is open and 0 are closed. Of the trial that contains KMT2A status and overt primary myelofibrosis as inclusion criteria, 1 is phase 2 (1 open) [4].

KMT2A is an inclusion criterion in 1 clinical trial for plasmablastic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains KMT2A status and plasmablastic lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

KMT2A is an inclusion criterion in 1 clinical trial for polycythemia vera, of which 1 is open and 0 are closed. Of the trial that contains KMT2A status and polycythemia vera as inclusion criteria, 1 is phase 2 (1 open) [4].

KMT2A is an inclusion criterion in 1 clinical trial for primary central nervous system lymphoma, of which 1 is open and 0 are closed. Of the trial that contains KMT2A status and primary central nervous system lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

KMT2A is an inclusion criterion in 1 clinical trial for primary cutaneous diffuse large B-cell lymphoma, leg type, of which 1 is open and 0 are closed. Of the trial that contains KMT2A status and primary cutaneous diffuse large B-cell lymphoma, leg type as inclusion criteria, 1 is phase 2 (1 open) [4].

KMT2A is an inclusion criterion in 1 clinical trial for primary effusion lymphoma, of which 1 is open and 0 are closed. Of the trial that contains KMT2A status and primary effusion lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

KMT2A is an inclusion criterion in 1 clinical trial for small lymphocytic leukemia, of which 0 are open and 1 is closed. Of the trial that contains KMT2A status and small lymphocytic leukemia as inclusion criteria, 1 is phase 1 (0 open) [4].

KMT2A is an inclusion criterion in 1 clinical trial for T-cell/histiocyte-rich large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains KMT2A status and T-cell/histiocyte-rich large B-cell lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

KMT2A is an inclusion criterion in 1 clinical trial for therapy-related chronic myelomonocytic leukemia, of which 1 is open and 0 are closed. Of the trial that contains KMT2A status and therapy-related chronic myelomonocytic leukemia as inclusion criteria, 1 is phase 1 (1 open) [4].

KMT2A is an inclusion criterion in 1 clinical trial for triple-hit lymphoma, of which 1 is open and 0 are closed. Of the trial that contains KMT2A status and triple-hit lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

KMT2A is an inclusion criterion in 1 clinical trial for waldenstrom macroglobulinemia, of which 1 is open and 0 are closed. Of the trial that contains KMT2A status and waldenstrom macroglobulinemia as inclusion criteria, 1 is phase 2 (1 open) [4].